Tuberculosis
Utilising ultra-sensitive molecular diagnostics QuantuMDx will be bringing gold-standard diagnostics into the community.
We are working with the Bill and Melinda Gates Foundation to develop technologies for rapid and low cost TB detection and drug susceptibility testing.
The Problem
Healthcare systems face many barriers, including a lack of finance, testing expertise and infrastructure, to the provision of TB diagnostics.
Increasing resistance to TB drugs and non-adherence due to the incredibly burdensome regimens has led companies to develop new treatments.
Whilst many of these drugs are still undergoing early stage trials, new regimens are expected to be available soon.
However without widespread drug sensitivity testing (DST), which is currently confined to centralised laboratories, inaccessible to many who need it, these drugs will not have full impact.
Increasing resistance to TB drugs and non-adherence due to the incredibly burdensome regimens has led companies to develop new treatments.
Whilst many of these drugs are still undergoing early stage trials, new regimens are expected to be available in 2018.
However without widespread drug sensitivity testing (DST), which is currently confined to centralised laboratories, inaccessible to many who need it, these drugs will not have full impact.
The average total cost incurred by TB patients in low-and middle-income countries is estimated at 20% - 40% of annual family income.
The Solution
QuantuMDx is utilising its superior multiplexing capability to develop a drug susceptibility test for the future drug regimens. We have partnered with FIND to overcome the many challenges of sample preparation.
SHARE THIS PAGE
Partnerships
Clinical development and trial partners, access to samples.
Global Partnerships, Global Vision
- DiagnosticsUnder the Tree
- Q-POC™Portable Diagnostics
Our portable, battery-operated molecular diagnostic device will provide sample-to-result testing in less than 20 minutes.
- Internet of Life™Networking Disease Data
Globally distributed Q-POC devices will geotag and anonymise pathogen data, and send it to the cloud for real-time disease and drug resistance monitoring.